Treatment of exacerbation of bronchoobstructive diseases during COVID-19

June 25, 2021

Today, the epidemiological situation with the spread of COVID-19 in Ukraine and around the world is only becoming more complicated. Despite the already significant data available on the prevalence and course of SARS-CoV-2 infection, the relevance of the problem of COVID-19 comorbidity and chronic lung disease is unquestionable due to the similarity of clinical manifestations, complexity of diagnosis and potential severity. Thus, current data suggest that patients with concomitant asthma and chronic obstructive pulmonary disease who are infected with SARS-CoV-2 are a vulnerable group with a complicated course and often an adverse outcome that requires control of bronchial obstructive syndrome symptoms. The problem of eliminating the exacerbation of asthma and chronic obstructive pulmonary disease is further complicated by the fact that the pandemic imposes significant restrictions on diagnostic and therapeutic measures, making it difficult to provide medical care to patients of this category during the pandemic at all stages. Therefore, today it is extremely important to find new therapeutic solutions that could ensure the control of bronchoobstructive diseases with the patient’s stay at home, without the need for hospitalization and involvement of medical staff in the treatment process.


  • 1. WHO (2017) Chronic obstructive pulmonary disease (COPD) (,of%20COPD%20globally%20in%202016.).
  • 2. Guziy O.V. (2019) Bronchoobstructive diseases: new clinical guidelines and the position of the Ministry of Health of Ukraine. UMJ, 5(133)(1): 14–16 (In Ukr.).
  • 3. Ministry of Health of Ukraine (2020) Adapted evidence-based clinical guideline «Bronchial asthma» ( (In Ukr.).
  • 4. GINA (2020) 2020 GINA MAIN REPORT (
  • 5. Manjra A.I., Price J., Hughes S. et al. (2000) Efficacy of nebulized fluticasone propionate compared with oral prednisolone in children with an acute exacerbation of asthma. Respir. Med., 94: 1206–1214. doi:10.1053/rmed.2000.0952.
  • 6. Vestbo J., Hurd S.S., Agustí A.G. et al. (2013) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am. J. Respir. Crit. Care Med., 187(4): 347–365. doi: 10.1164/rccm.201204-0596PP.
  • 7. Chapman K.R., Mannino D.M., Soriano J.B. et al. (2006) Epidemiology and costs of chronic obstructive pulmonary disease. Eur. Respir. J., 27(1): 188–207. doi: 10.1183/09031936.06.00024505.
  • 8. Ministry of Health of Ukraine (2020) Chronic obstructive pulmonary disease. Adapted clinical guidelines based on evidence (In Ukr.).
  • 9. Dobrianskyi D.V., Holyshkin D.V., Los O.V. et al. (2020) Investigation of the distribution of particles of drugs with the help of cascade impactor (
  • 10. Dhand R., Dolovich M., Chipps B. et al. (2012) The role of nebulized therapy in the management of COPD: evidence and recommendations. COPD, 9(1): 58–72. doi: 10.3109/15412555.2011.630047.
  • 11. Rafferty P., Beasley R., Holgate S.T. (1988) Comparison of the efficacy of preservative free ipratropium bromide and Atrovent nebuliser solution. Thorax, 43(6): 446–450. doi: 10.1136/thx.43.6.446.
  • 12. Sahasranaman S., Issar M., Hochhaus G. (2005) Metabolism of mometasone furoate and biological activity of the metabolites. Drug Metabolism and Disposition, 34(2): 225–233. DOI: 10.1124/dmd.105.005702.
  • 13. Dzyublik Ya.O., Bororova OL, Patiuk Yu.O. (2021) Expediency and safety of nebulizer therapy in patients with infectious diseases of the respiratory tract during the pandemic COVID-19. Ukr. Pulmonol. J., 1: 31–38. (In Ukr.).
  • 14. World Health Organization (2020) Clinical management of COVID-19: interim guidance (
  • 15. Beasley R., Fishwick D., Miles J.F. et al. (1998) Preservatives in nebulizer solutions: risks without benefit. Pharmacotherapy, 18(1): 130–139.
  • 16. Utell M.J., Morrow P.E., Speers D.M. et al. (1983) Airway responses to sulfate and sulfuric acid aerosols in asthmatics. An exposure-response relationship. Am. Rev. Respir. Dis., 128(3): 444–450. doi: 10.1164/arrd.1983.128.3.444.
  • 17. Kokulu K., Öner H., Özen C. et al. (2019) Pharmacologic anisocoria due to nebulized ipratropium bromide: A diagnostic challenge. Am. J. Emerg. Med., 37(6): 1217.e3–1217.e4.
  • 18. Yudina L.V. (2014) Elimination of exacerbations of bronchial asthma — fast and affordable.Asthma and allergies, 3: 110–114 (In Rus.).
  • 19. Billington C.K., Penn R.B., Hall I.O. (2017) β2 Agonists. Handb. Exp. Pharmacol., 237: 23–40. doi: 10.1007/164_2016_64.
  • 20. Avdeev S.N., Aisanov Z.R., Arkhipov V.V. et al. (2001) Inhaled glucocorticosteroids for obstructive pulmonary disease ( (In Rus.).
  • 21. Corren J., Berkowitz R., Murray J.J. et al. (2003) Comparison of once-daily mometasone furoate versus once-daily budesonide in patients with moderate persistent asthma. Int. J. Clin. Pract., 57(7): 567–572.
  • 22. Kovalenko S.V. (2014) Experience in the use of inhaled fluticasone propionate for the treatment of exacerbations of COPD in the pulmonology department. Asthma and allergy, 1. (In Ukr.).
  • 23. Pristupa L.N., Guyva T.O., Kmita V.V. (2014) The effectiveness of nebulizer therapy in the treatment of exacerbations of bronchial asthma. Asthma and allergies, 4: 66–70. (In Ukr.).
  • 24. Reddel H., Fenton N., Gowan J. et al. (2014) The Australian asthma handbook: Practical and accessible guidelines for primary care (
  • 25. Barskaya L.Ya., Frolova T.V., Okhapkina O.V. (2014) Experience of using the drug Nebufluzon® in the treatment of obstructive syndrome in children. Pediatrician, 2(31): 38–40. (In Rus.).
  • 26. Ostrovsky M.M. (2020) Nebulizer therapy — features of application during the COVID-19 pandemic from the point of view of global initiatives. Asthma and allergy, 4: 67–68. DOI: 10.31655/2307-3373-2020-4-67-68. (In Ukr.).